Literature DB >> 7585222

Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate.

J B Nelson1, S P Hedican, D J George, A H Reddi, S Piantadosi, M A Eisenberger, J W Simons.   

Abstract

Prostate cancer is the second most common cause of death from cancer in U.S. men, and advanced, hormone-refractory disease is characterized by painful osteoblastic bone metastases. Endothelin-1, more commonly known as a potent vasoconstrictor, is a normal ejaculate protein that also stimulates osteoblasts. We show here that plasma immunoreactive endothelin concentrations are significantly elevated in men with metastatic prostate cancer and that every human prostate cancer cell line tested produces endothelin-1 messenger RNA and secretes immunoreactive endothelin. Exogenous endothelin-1 is a prostate cancer mitogen in vitro and increases alkaline phosphatase activity in new bone formation, indicating that ectopic endothelin-1 may be a mediator of the osteoblastic response of bone to metastatic prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585222     DOI: 10.1038/nm0995-944

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  119 in total

Review 1.  Angiogenesis in cancer: the role of endothelin-1.

Authors:  K Dawas; M Loizidou; A Shankar; H Ali; I Taylor
Journal:  Ann R Coll Surg Engl       Date:  1999-09       Impact factor: 1.891

2.  Endothelin-1 and osteoblastic metastasis.

Authors:  Gregory R Mundy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-08       Impact factor: 11.205

3.  Big endothelin changes the cellular miRNA environment in TMOb osteoblasts and increases mineralization.

Authors:  Michael G Johnson; Jasmin Kristianto; Baozhi Yuan; Kathryn Konicke; Robert Blank
Journal:  Connect Tissue Res       Date:  2014-08       Impact factor: 3.417

Review 4.  Endothelin receptor antagonists.

Authors:  Joel B Nelson
Journal:  World J Urol       Date:  2005-01-15       Impact factor: 4.226

Review 5.  Targeted approaches for the management of metastatic prostate cancer.

Authors:  Kathleen W Beekman; Maha Hussain
Journal:  Curr Oncol Rep       Date:  2006-05       Impact factor: 5.075

6.  Endothelin-a receptor antagonists and advanced prostate cancer.

Authors:  Masood A Khan; Alan W Partin
Journal:  Rev Urol       Date:  2004

7.  Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

Authors:  David I Quinn; Catherine M Tangen; Maha Hussain; Primo N Lara; Amir Goldkorn; Carol M Moinpour; Mark G Garzotto; Philip C Mack; Michael A Carducci; J Paul Monk; Przemyslaw W Twardowski; Peter J Van Veldhuizen; Neeraj Agarwal; Celestia S Higano; Nicholas J Vogelzang; Ian M Thompson
Journal:  Lancet Oncol       Date:  2013-07-17       Impact factor: 41.316

8.  Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.

Authors:  Debraj GuhaThakurta; Nadeem A Sheikh; Li-Qun Fan; Harini Kandadi; T Craig Meagher; Simon J Hall; Philip W Kantoff; Celestia S Higano; Eric J Small; Thomas A Gardner; Kate Bailey; Tuyen Vu; Todd DeVries; James B Whitmore; Mark W Frohlich; James B Trager; Charles G Drake
Journal:  Clin Cancer Res       Date:  2015-02-03       Impact factor: 12.531

Review 9.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

10.  Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.

Authors:  Peter Jantscheff; Vittorio Ziroli; Norbert Esser; Ralph Graeser; Jessica Kluth; Alena Sukolinskaya; Lenka A Taylor; Clemens Unger; Ulrich Massing
Journal:  Clin Exp Metastasis       Date:  2009-09-26       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.